RecruitingPhase 1NCT07823205

A Study to Evaluate Different Oral Formulations of KT-621

A Phase 1, Open-Label, Crossover Study to Evaluate the Relative Bioavailability of Different Oral Formulations of KT-621 in Healthy Adult Participants

Sponsor

Kymera Therapeutics, Inc.

Enrollment

54 participants

Start Date

Oct 1, 2026

Study Type

INTERVENTIONAL

Conditions

Healthy Participants

Summary

This is a Phase I study to evaluate the relative bioavailability and safety and tolerability of different oral formulations of KT-621 in healthy adult participants.

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called KT-621, a drug called KT-621, and others for people with healthy participants. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.